55.55/0) with 10.1% CR. Median survival wvas similar in the two arms at 6.4 months (950o CI. 4.9 -7.3 months) and 5.8 months (95%o CI. 4.0-6.6 months) respectively. SurVxial at 1 year was 9.90o (950o CI. 5.0-18.50o) and 8.90o (95°o CI. 4.6 -16.6°oo). The 9500 CI for the difference in survi-al at 1 xear is 7.090o to -9.090°. Haematological toxicity and treatment delays owing to infection w-ere more frequent with the 10 11 day regimen but other toxicities were equal in both arms. Other aspects of quality of life were measured in a small representative cohort of patients using a daily diary card (DDC). There was a trend of improved quality of life on the 10 11 dav arm. but there was little difference between the tu-o treatments. The trial show-s that a lowdose high-frequencv regimen with the same DI as conventionall1 scheduled chemotherapy ezives similar response rates and survival. This and other modifications of the schedule may offer new approaches to palliative treatment of advanced cancer. However. in this trial there w-as no significant benefit in toxicity or other aspects of quality of life.
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Keywords: small-cell lung cancer: palliation: chemotherapx Despite the chemosensitivity of small-cell lung cancer there has been little improvement over the last 10 years in response rates and survival for those patients who have extensive disease (Comis, 1993) and particularly for those with poor prognostic features. Overall. only 2.2% of extensive disease patients Will be alive at 2 years ). For these patients and for elderly patients. attention has been turned to palliative chemotherapy. such as the use of oral etoposide Carney. 1994: Carney et al.. 1990 ). Other approaches to palliation are possible. It has been suggested (Hryniuk. 1988 ) that dose intensity of chemotherapy is a major determinant of response and survival in cancer. Since acute chemotherapy toxicity is related to dose we hypothesised that major dose reduction might lessen the acute toxicity of chemotherapy without worse survival provided that the dose intensity (DI) of treatment was maintained.
The present report describes the results of a trial in which this novel method of palliation has been assessed. A 3 weekly conventional alternating chemotherapy regimen of cyclophosphamide. doxorubicin and vincristine and cisplatin and etoposide based on that introduced by the National Cancer Institute of Canada (Feld et al.. 1987) was used as the reference treatment. These drug combinations have been widely used in the treatment of SCLC. The regimen was modified for poor prognosis patients by reducing the doses of cyclophosphamide from 1 g m-' to 600 mg m-and the cisplatin from 25 mg m--on days 1-3 to 60 mg m-' on dav 1. The etoposide was modified to alloxx the drug to be given by mouth on days 2 and 3. In this sA-ay each cycle had only one day of intravenous treatment. The novel regimen consisted of the same drugs given at half the dose on each cycle, but at tWice the frequency. Quality of hfe was assessed in a small cohort using a daily diary card (Geddes et al.. 1990 ).
Between July 1988 and December 1992. 167 patients were entered into the study from the participating centres. Patients were eligible if they had SCLC diagnosed by histology (bronchial biopsy. lymph node biopsy) or by cytology from bronchial washings, pleural aspirate or sputum specimen: if they were aged 75 years or less and had both extensive disease and poor prognostic factors defined as a performance status of ECOG 2 or 3 and or an alkaline phosphatase (ALP) greater than 1.5 times the upper limit of normal (Rawson and Peto. 1990: Souhami et al.. 1985) . Renal function had to be adequate for cisplatin chemotherapy. Patients A-ere excluded if they had a previous malignancy other than non- Chemotherapy DI was calculated for the duration of the administered chemotherapy, i.e. as measured from the first day of the first chemotherapy cycle to the first day of the last chemotherapy cycle. Dose reductions of myelosuppresive drugs were planned so they would affect all drugs in equal proportion; in this way no assumption of equivalent antitumour effect of each component should affect the DI calculation and DI can be calculated for the regimen as a whole. The graphical method of plotting the results has been described previously (Miles et al., 1991; Souhami et al., 1994) . The final calculated maximum achieved dose intensity corresponds to the formula (RDo/IDo)/(RDu/IDu), where RDo = received dose, IDo = intended dose, RDu = received duration and IDu = intended duration.
The end points of the trial were death from cancer, progression and quality of life. The trial was designed to have a 90% chance of detecting a 10% improvement in 1 year survival for the 3 weekly arm at the significance level of 5% The number of courses received on the 10/11 day arm was double that on the 3 weekly arm (7.5 and 3.7 respectively, Table IV ). The main reason for failure to complete therapy (Table V) was haematological toxicity with 20% of patients receiving the 10/11 day treatment having reductions compared with 8% of the 3 weekly patients. There was no difference in the number of treatment delays, 14.7% (10/11 day) and 16.3% (3 weekly). Delays owing to infection occurred in 9.3% of patients on the 10/11 day protocol compared with 1.2% of the 3 weekly patients. There was no difference in each arm for the proportion of patients not completing chemotherapy (59.0%, 10/11 day and 57.3%, 3 weekly). PaFUiave dchuuah.rapy in SCIC x LE James et i 1566 completing chemotherapy were tumour progression, toxicity and patient's wish to discontinue. These were equal in both arms.
Response and survival Response to treatment is shown in Table VI . The overall response rate was 58.93% on the 10/11 day arm (CR+PR) and 44.9% on the 3 weekly arm (CR+PR). In the 10/11 day arm ten patients (12.8%) were inevaluable for response. Two patients died before the first cycle of chemotherapy, seven progressed or withdrew before cycle 2 and there was one unrelated death. In the 3 weekly arm 22 patients (24.7%) were inevaluable according to the protocol criteria. Two died before the first cycle and another refused chemotherapy. Twelve patients died before the second cycle, three withdrew, three died of other causes and there was one toxic death. All these patients are included in the survival analysis.
Overall survival is shown in Figure 1 . There was no significant difference in survival between the two groups. Median survival (MS) on the 10/11 day arm was 6.4 months (95% CI, 4.9-7.3) and for the 3 weekly arm MS was 5.8 months (95% CI, 4.0-6.6). Survival at 1 year on the 10/11 day arm was 9.9% (95% CI, 5.0-18.5) and 8.9% (95% CI, 4.6-16.6) on the 3 weekly arm. Survival at 2 years was 4.3% (95% CI, 1.6-11.3) and 2.5% (95% CI, 0.7-8.2) respectively. The 95% CI, for the absolute difference in survival at 1 year is -7.09% to +9.09% and at 2 years is -5% to + 7.34%. The trial excludes a survival difference of 15% at 80% power. The hazard ratio for survival was 0.91 in favour of the 10/ 11 day arm (95% CI, 0.79-1.52) Using these data we can produce limits for the size of the possible benefit of one treatment compared with another (Haybittle, 1979) . For the 10/11 day regimen, at 1 year there is a 1 in 8 chance of 8% benefit, a 1 in 40 chance of 12% and 1 in 200 of 15% improvement in survival. There was no significant difference between the two groups with respect to site of relapse, the most common first site being at the primary tumour.
Toxicity and quality of life The major toxicities were haematological, nausea and vomiting (Table VII) . Leucopenia was more frequent with the 10/11 day regimen with more grade 1-2 infections in this group. Other toxicities were equally distributed, in particular nausea and vomiting were no less frequent or severe with the 10/11 day treatment.
A cohort of 49 patients, which consisted of all patients entered from one centre and its associated hospitals, were asked to complete DDCs. Of these, 14 refused (eight and six in 10/11 day and 3 weekly arms respectively. No significant differences were found in the distributions of age, sex and performance status between the arms in the QOL group or when compared with the full set of trial patients. There was no difference in dose intensity between groups or between arms (Table VIII) . Compliance was 62% (68.6% in the 10/11 day and 52% in the 3 weekly arm) for the intended period of analysis. Because of the fall in number of respondents over time, the first 80 days were used for analysis. During this time there was a minimum of ten respondents in each arm and compliance was 79.3% in the 10/11 day arm and 82.6% in the 3 weekly arm.
Percentage of scores which reported any adverse event (i.e. a value different from zero) were slightly but significantly worse with respect to vomiting, happiness, appetite, general well-being and activity in the 3 weekly arm (Table IX) but there was no difference in reported nausea, pain and sleep.
There was no significant correlation between physicianreported nausea and vomiting and the relevant diary cards, but there was a correlation of 0.625 between ECOG and DDC activity scores (205 courses).
Disasso
The hypothesis which led to this study was that, if DI is the major determinant of tumour response and survival (rather than drug schedule) it might be possible to reduce chemotherapy toxicity without loss of anti-tumour effect by a low-dose/high frequency regimen. SCLC patients with extensive disease and poor prognostic features are rarely cured by chemotherapy. Trials of palliation are therefore of great importance in this group (Comis, 1993; Byrne and Carney, 1994) . Trials of chemotherapy dosage in SCLC have not shown a benefit from a modest increase in dose above the conventional therapeutic level (Klasa et al., 1991; Ihde et al., 1994; Figueredo et al., 1985) . In other cancers dose reduction without increase in frequency has been shown to reduce response and survival (Tannock et al., 1987) . We chose the regimen described by Feld et al. (1987) as a basis for our study since this represents a standard chemotherapy combination in SCLC. We modified the drug dosages to allow this regimen to be given to a group of patients with an expected poor prognosis. The results reported here indicate that the strategy of half-dose/double (Rawson and Peto, 1990; Souhami et al., 1985) .
We have found, contrary to our starting hypothesis, that the low-dose/high frequency regimen was not a preferred method of palliation. Leucopenia occurred more often with this regimen leading to an increased frequency of dose reduction. Myelosuppression was also the major toxicity of the weekly regimens described by Souhami et al. (1994) We conclude that this novel method of palliation is not of value in SCLC. However, the fact that response and survival were maintained implies that other variations of dose and schedule could be explored in SCLC and other advanced cancers in which the aim is to palliate without loss of antitumour efficacy.
